Microbes, immunity and multiple sclerosis

Current Immunology Reviews

Volumn 7, Issue 1, 2011, Pages 75-82

  Fernandez, Ana Maria ^a   PapaisAlvarenga, Marcos ^a   Fernandez, Victoria ^a   Guerrero, Miguel ^a   Fernandez, Oscar ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Chlamydophila pneumoniae; EBV; HHV 6; Immunity; Microbes; Multiple sclerosis

Indexed keywords

MYELIN; SUPERANTIGEN;

ARTICLE; AUTOIMMUNE DISEASE; CANINE DISTEMPER MORBILLIVIRUS; CHLAMYDOPHILA PNEUMONIAE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; HUMAN; HUMAN HERPESVIRUS 6; IMMUNE RESPONSE; IMMUNITY; INCIDENCE; MEASLES VIRUS; MULTIPLE SCLEROSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; T LYMPHOCYTE; VARICELLA ZOSTER VIRUS;

EID: 79551662911     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339511794474262     Document Type: Article

References (165)

1. th ed. Madrid: Elsevier 2004; pp. 1456-65.
2. Poser CM. Viking voyages: the origin of multiple sclerosis? Anessay in medical history. Acta Neurol Scand Suppl 1995; 161: 11-22.
3. Ebers GC, Yee IM, Sadovnick AD, Duquette P. Conjugal multiplesclerosis: population-based prevalence and recurrence risks inoffspring. Canadian Collaborative Study Group. Ann Neurol 2000; 48: 927-31.
4. Dean G, Gray R. Do nurses or doctors have an increased risk ofdeveloping multiple sclerosis? J Neurol Neurosurg Psychiatry 1990; 53: 899-902.
5. Rosati G. The prevalence of multiple sclerosis in the world: anupdate. Neurol Sci 2001; 22: 117-39.
6. Elian M, Dean G. Multiple sclerosis among the United Kingdombornchildren of immigrants from the West Indies. J Neurol Neurosurg Psychiatry 1987; 50: 327-32.
7. Dean G, Kurtzke JF. On the risk of multiple sclerosis according toage at immigration to South Africa. BMJ 1971; 3: 725-9.
8. Alter M, Kahana E, Loewenson R, Polman CH. Migration and riskof multiple sclerosis. Neurology 1978; 28: 1089-93.
9. Kahana E, Zilber N, Abramson JH, Biton V, Leibowitz Y, Abramsky O. Multiple sclerosis: genetic versus environmentalaetiology: epidemiology in Israel updated. J Neurol 1994; 241: 341-6.
10. Murray TJ. Multiple sclerosis: the history of a disease. New York:Demos 2005.
11. nd ed. Madrid: McGraw-Hill/Interamericana 2005; pp. 9-21.
12. Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiplesclerosis: current pathophysiological concepts. Lab Invest 2001; 81: 263-81.
13. Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis ofmultiple sclerosis: an update on immunology. Curr Opin Neurol 2002; 15: 227-31.
14. Liblau RS, Fontaine B. Recent advances in immunology inmultiple sclerosis. Curr Opin Neurol 1998; 11: 293-8.
15. Gran B, Hemmer B, Vergelli M, McFarland HF, Martin R. Molecular mimicry and multiple sclerosis: degenerate T-cellrecognition and the induction of autoimmunity. Ann Neurol 1999; 45: 559-67.
16. Albert LJ, Inman RD, Polman CH. Molecular mimicry andautoimmunity. N Engl J Med 1999; 341: 2068-74.
17. Johnson HM, Torres BA, Soos JM. Superantigens: structure andrelevance to human disease. Proc Soc Exp Biol Med 1996; 212: 99-109.
18. Brocke S, Piercy C, Steinman L, Polman CH. Superantigens indemyelinating disease. Springer Semin Immunopathol 1996; 18: 51-6.
19. Vanderlugt CL, Begolka WS, Neville KL, et al. The functionalsignificance of epitope spreading and its regulation by costimulatorymolecules. Immunol Rev 1998; 164: 63-72.
20. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiplesclerosis patients and healthy subjects: epitope spreading versusclonal persistence. Brain 2000; 123: 508-18.
21. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol 1996; 8: 831-6.
22. Tuohy VK, Yu M, Yin L, et al. The epitope spreading cascadeduring progression of experimental autoimmune encephalomyelitisand multiple sclerosis. Immunol Rev 1998; 164: 93-100.
23. Kumar V. Determinant spreading during experimental autoimmuneencephalomyelitis: is it potentiating, protecting or participating inthe disease? Immunol Rev 1998; 164: 73-80.
24. Voskuhl RR. Myelin protein expression in lymphoid tissues:implications for peripheral tolerance. Immunol Rev 1998; 164: 81-92.
25. Compston A, Confavreux C. The distribution of multiple sclerosis. In: Compston A, Ed. McAlpine's Multiple Sclerosis, 4th ed. Churchill Livingstone: Elsevier 2006; pp. 71-111.
26. Giovannoni G, Ebers G. Multiple sclerosis: the environment andcausation. Curr Opin Neurol 2007; 20: 261-8.
27. Kurtzke JF. MS epidemiology world wide. One view of currentstatus. Acta Neurol Scand Suppl 1995; 161: 23-33.
28. Kurtzke JF, Page WF. Epidemiology of multiple sclerosis in USveterans: VII. Risk factors for MS. Neurology 1997; 48: 204-13.
29. Kurtzke JF. Epidemiology of multiple sclerosis. Does this reallypoint toward an etiology? Lectio Doctoralis. Neurol Sci 2000; 21: 383-403.
30. Pryse-Phillips W. The epidemiology of multiple sclerosis. In: Cook S, ed. Handbook of multiple sclerosis. New York: Marcel Dekker 1990; pp. 1-24.
31. Pugliatti M, Sotgiu S, Solinas G, et al. Multiple sclerosisepidemiology in Sardinia: evidence for a true increasing risk. Acta Neurol Scand 2001; 103: 20-6.
32. Grimaldi LM, Salemi G, Grimaldi G, et al. High incidence andincreasing prevalence of MS in Enna (Sicily), southern Italy. Neurology 2001; 57: 1891-3.
33. Grytten N, Glad SB, Aarseth JH, Nyland H, Midgard R, Myhr KM. A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. Neurology 2006; 66: 182-6.
34. Sundstrom P, Nystrom L, Forsgren L. Incidence (1988-97) andprevalence (1997) of multiple sclerosis in Vasterbotten County innorthern Sweden. J Neurol Neurosurg Psychiatry 2003; 74: 29-32.
35. Sarasoja T, Wikstrom J, Paltamaa J, Hakama M, Sumelahti ML. Occurrence of multiple sclerosis in central Finland: a regional andtemporal comparison during 30 years. Acta Neurol Scand 2004; 110: 331-6.
36. Pugliatti M, Rosati G, Carton H, et al. The epidemiology ofmultiple sclerosis in Europe. Eur J Neurol 2006; 13: 700-22.
37. Modrego PJ, Pina MA. Trends in prevalence and incidence ofmultiple sclerosis in Bajo Aragon, Spain. J Neurol Sci 2003, 216: 89-93.
38. Moreau T. Prevalence of multiple sclerosis in France and its 22regions. [P350] ECTRIMS: Prague 2007.
39. Ragonese P, Salemi G, D'Amelio M, Gammino M, Aridon P, Savettieri G. Multiple sclerosis in southern Europe: Monreale City, Italy. A twenty-year follow-up incidence and prevalence study. Neuroepidemiology 2004; 23: 306-9.
40. Grimaldi LM, Palmeri B, Salemi G, et al. High prevalence and fastrising incidence of multiple sclerosis in Caltanissetta, Sicily, southern Italy. Neuroepidemiology 2007; 28: 28-32.
41. Nicoletti A, Patti F, Lo FS, et al. Possible increasing risk ofmultiple sclerosis in Catania, Sicily. Neurology 2005; 65: 1259-63.
42. Ranzato F, Perini P, Tzintzeva E, et al. Increasing frequency ofmultiple sclerosis in Padova, Italy: a 30 year epidemiologicalsurvey. Mult Scler 2003; 9: 387-92.
43. Peterlin B, Ristic S, Sepcic J, et al. Region with persistent highfrequency of multiple sclerosis in Croatia and Slovenia. J Neurol Sci 2006; 247: 169-72.
44. Barnett MH, Williams DB, Day S, Macaskill P, McLeod JG. Progressive increase in incidence and prevalence of multiplesclerosis in Newcastle, Australia: a 35-year study. J Neurol Sci 2003; 213: 1-6.
45. Piedrabuena R. High prevalence of multiple sclerosis in the city of Oliva, Cordoba, Argentina. Arq Neuropsiquiatr 2004; 62: 13.
46. Arrambide G. The prevalence of multiple sclerosis in the city of San Pedro GG, Mexico. Arq Neuropsiquiatr 2004; 62: 11.
47. Rivera VM. La esclerosis múltiple en Latinoamérica. Señales deun aumento en la incidencia. MEDICO Interamericano 2000; 19: 458-65.
48. Cabre P. Environmental changes and epidemiology of multiplesclerosis in the French West Indies. J Neurol Sci 2009; 286: 58-61
49. Ruiz M. Pauta de introducción de la esclerosis múltiple en Cuba. Rev Neurol 2002; 35: 1180.
50. Houzen H, Niino M, Hata D, et al. Increasing prevalence andincidence of multiple sclerosis in northern Japan. Mult Scler 2008; 14: 887-92.
51. Alonso A, Hernan MA. Temporal trends in the incidence ofmultiple sclerosis: A systematic review. Neurology 2008; 71: 129-35.
52. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiplesclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5: 932-6.
53. Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005; 98: 195-202.
54. Payne FE, Baublis JV, Itabashi HH. Isolation of measles virus fromcell cultures of brain from patient with subacute sclerosingpanencephalitis. N Engl J Med 1969; 281: 585-616.
55. Padgett BL, Walker DL, Zu Rhein GM, et al. Cultivation ofpapova-like virus from human brain with progressive multifocalleucoencephalopathy. Lancet 1971; 1: 1257-60.
56. Correale J, Fiol M, Gilmore W. The risk of relapses in multiplesclerosis during systemic infections. Neurology 2006; 67: 652-9.
57. Granieri E, Casetta I, Tola MR, Ferrante P. Multiple sclerosis:infectious hypothesis. Neurol Sci 2001; 22: 179-85.
58. Marie P. Sclérose en plaques et maladies infectieuses. Progrès Med 1884; 12: 287-9, 305-7, 349-51, 365-6.
59. Kuhn P, Steiner G. Über die Ursache der multiplen Sklerose. Med Klin 1917; 13: 1007.
60. Kuhn P, Steiner G. Multiplin Sklerose. Stschr Hyg Infect 1920; 90: 417-22.
61. Ichelson RR. Cultivation of spirochetes from spinal fluids ofmultiple sclerosis cases and negative controls. Proc Soc Exp Biol 1957; 95: 57-8.
62. McAlpine D, Lumsden CE, Acheson ED. Multiple Sclerosis: AReappraisal, 2nd ed. Edinburgh: E & S Livingston 1972.
63. Chevassut K. Aetiology of disseminated sclerosis. Lancet 1930; 1: 522-60.
64. Purves-Stewart J. A specific vaccine treatment in disseminatedsclerosis. Lancet 1930; 1: 560-4.
65. Purves-Stewart J. The etiology and treatment of disseminatedsclerosis. J Nerv Ment Dis 1930; 72: 652-60.
66. Carmichael EA. The aetiology of disseminate sclerosis: Somecriticisms of recent work especially with regard to the "Spherulainsularis". Proc R Soc Med 1931; 34: 591-9.
67. Le Gac P. Nouvelles données sur la sclérose en plaques. J MédBourdeaux 1960; 137: 346.
68. Le Gac P. Le traitement de la sclérose en plaques d'originerickettsienne et néorickettsienne. J Méd Bordeaux 1960; 137: 577-89.
69. Giovannoni G, Cutter GR, Luneman J, et al. Infectious causes ofmultiple sclerosis. Lancet Neurol 2006; 5: 887-94.
70. Koch R. The aetiology of tuberculosis (translation of Die Aetiologie der Tuberculose [1882]). New York, UDA: Dover Publications 1942.
71. Fredericks DN, Relman DA. Sequence-based identification ofmicrobial pathogens: a reconsideration of Koch's postulates. Clin Microbiol Rev 1996; 9: 18-33.
72. Hill AB. The environment and disease: association or causation?Proc R Soc Med 1965; 58: 295-300.
73. Sadovnick AD, Scheifele DW. School-based hepatitis Bvaccination programme and adolescent multiple sclerosis. Lancet 2000; 355: 549-50.
74. Souberand B, Boisnard F, Bruel M, et al. Central nervous systemdemyelinating disease following hepatitis B vaccination with Gen Hevac B. Review of ten years of spontaneous notifications(1989-1998). Presse Med 2000; 29: 775-80.
75. Monteyne P, Andre FE. Is there a causal link between hepatitis Bvaccination and multiple sclerosis? Vaccine 2000; 18: 1994-2001.
76. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccinationand the risk of multiple sclerosis. N Engl J Med 2001; 344: 327-32.
77. Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the riskof relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. New Engl J Med 2001; 344: 319-26.
78. De Stefano F, Verstraeten T, Jackson LA, et al. Vaccinations andrisk of central nervous system demyelinating diseases in adults. Arch Neurol 2005; 60: 504-9.
79. Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis Bvaccine and the risk of multiple sclerosis a prospective study. Neurology 2005; 63: 838-42.
80. Granieri E, Casetta I. Common childhood and adolescent infectionsand multiple sclerosis. Neurology 1997; 49: S42-54.
81. Adams JM, Imagawa DT. Measles antibodies in multiple sclerosis. Proc Soc Exp Biol Med 1962; 111: 562-6.
82. Murray TJ, Murray SJ. Characteristics of patients found not to havemultiple sclerosis. Can Med Assoc J 1984; 131: 336-7.
83. Poskanzer DC, Schapiro K, Miller H. Multiple sclerosis andpoliomyelitis. Lancet 1963; 2: 917-21.
84. Sibley WA, Foley JM. Measles antibodies in multiple sclerosis. Trans Am Neurol Assoc 1963; 88: 277-81.
85. Larner AJ. Aetiological role of viruses in multiple sclerosis: areview. J R Soc Med 1986; 79: 412-7.
86. Compston DAS, Vakarelis BN Paul E, McDonald WI, Batchelor JR, Mims CA. Viral infection in patients with multiple sclerosisand HLA-DR matched controls. Brain 1986; 109: 325-44.
87. Martyn CN, Cruddas M, Compston DAS. Symptomatic Epstein-Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 167-8.
88. Bager P, Nielsen NM, Bihrmann K, et al. Childhood infections andrisk of multiple sclerosis. Brain 2004; 127: 2491-7.
89. Marrie RA, Wolfson C. Multiple sclerosis and varicella zoster virusinfection: a review. Epidemiol Infect 2001; 127: 315-25.
90. Kurtzke JF, Hyllested K. Multiple sclerosis in the Faeroe Islands. 1. Clinical and epidemiological features. Ann Neurol 1979; 5: 6-21.
91. Kurtzke JF, Hyllested K. Multiple sclerosis in the Faeroe Islands. 2. Clinical update, transmission, and the nature of MS. Neurology 1986; 36: 307-28.
92. Kurtzke JF, Hyllested K. Multiple sclerosis in the Faeroe Islands. 3. An alternative assessment of the three epidemics. Acta Neurol Scand 1987; 76: 317-39.
93. Kurtzke JF, Hyllested K. Multiple sclerosis in the Faeroe Islands. 4. Clinical update, transmission, and the nature of MS. Neurology 1986; 36: 307-28.
94. Kurtzke JF, Hyllested K, Heltberg A, Olsen A. Multiple sclerosis inthe Faeroe Islands. 5. The occurrence of the fourth epidemic asvalidation of transmission. Acta Neurol Scand 1993; 88: 161-73.
95. Cook SD, Dowling PC. A possible association between house petsand multiple sclerosis. Lancet 1978; 1: 980-2.
96. Frutos-Alegria MT, Beltran-Blasco I, Molto-Jorda J, Diaz-Marin C, Matias-Guiu J. The epidemiology of multiples sclerosis in Alcoi. Analytical data. Rev Neurol 2002; 34: 813-6.
97. Frutos-Alegria MT, Beltran-Blasco I, Quilez-Iborra C, Molto-Jorda J, Diaz-Marin C, Matias-Guiu J. A control and case study ofmultiple sclerosis in the Alicante and Villajoyosa areas. Rev Neurol 2002; 34: 1013-6.
98. Sylvester DL, Poser CM. Association of multiple sclerosis withdomestic animals and household pets. Ann Neurol 1979; 5: 207-9.
99. Zorzon M, Zivadinov R, Nasuelli D, et al. Risk factors of multiplesclerosis: a case-control study. Neurol Sci 2003; 24: 242-7.
100. Hernan MA, Zhang SM, Lipworth L, Olek MJ, Ascherio A. Multiple sclerosis and age at infection with common viruses. Epidemiology 2001; 12: 301-6.
101. Carp RI, Licursi PC, Merz PA, Merz GS. Decreased percentage ofpolymorphonuclear neutrophils in mouse peripheral blood afterinoculation with material from MS patients. J Exp Med 1972; 136: 618-29.
102. Johnson RT. Viral infections of the Nervous System. New York:Raven Press 1982.
103. Chmielewska-Badora J, Cisak E, Dutkiewicz J. Lyme borreliosisand multiple sclerosis: any connection? A seroepidemic study. Ann Agric Environ Med 2000; 7: 141-3.
104. Brorson O, Brorson SH, Henriksen TH, Skogen PR, Schoyen R. Association between multiple sclerosis and cystic structures incerebrospinal fluid. Infection 2001; 29: 315-9.
105. Cosby SL, McQuaid S, Taylor MJ, et al. Examination of eightcases of multiple sclerosis and 56 neurological and nonneurologicalcontrols for genomic sequences of measles virus, canine distemper virus, simian virus 5 and rubella virus. J Gen Virol 1989; 70: 2027-36.
106. Bangham CRM, Nightingale S, Cruickchank JK, et al. PCRanalysis from multiple sclerosis patients for the presence of HTLV-1. Science 1989; 246: 821-4.
107. Hackett J, Swanson P, Leathy D, et al. Search for retrovirus inpatients with multiple sclerosis. Ann Neurol 1996; 40: 805-9.
108. Perron H, Garson JA, Bedin F, et al. Molecular identification of anovel retrovirus repeatedly isolated from patients with multiplesclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci USA 1997; 94: 7583-8.
109. Dolei A, Serra C, Mameli G, et al. Multiple sclerosis-associatedretrovirus (MSRV) in Sardinian MS patients. Neurology 2002; 58: 471-3.
110. Sotgiu S, Serra C, Mameli G, et al. Multiple sclerosis-associatedretrovirus and MS prognosis: An observational study. Neurology 2002; 59: 1071-3.
111. Perron H, Perin JP, Rieger F, Alliel PM. Particle-associatedretroviral RNA and tandem RGH/HERV-W copies on humanchromosome 7q: possible components of a 'chain-reaction'triggered by infectious agents in multiple sclerosis? J Neurovirol 2000; 6: 67-75.
112. Christensen T, Dissing, Sorensen P, et al. Molecularcharacterization of HERV-H variants associated with multiplesclerosis. Acta Neurol Scand 2000; 101: 229-38.
113. Perron H, Firouzi R, Tuke P, et al. Cell cultures and associatedretroviruses in multiple sclerosis. Collaborative Research Group on MS. Acta Neurol Scand Suppl 1997; 169: 22-31.
114. Sriram S, Stratton CW, Yao S, et al. Chlamydia pneumoniaeinfection of the central nervous system in multiple sclerosis. Ann Neurol 1999; 46: 6-14.
115. Derfuss T, Gurkov R, Then Bergh F, et al. Intrathecal antibodyproduction against Chlamydia pneumoniae in multiple sclerosis ispart of a polyspecific immune response. Brain 2001; 124: 1325-35.
116. Buljevac D, Verkooyen RP, Jacobs BC, et al. Chlamydiapneumoniae and the risk for exacerbation in multiple sclerosispatients. Ann Neurol 2003; 54: 828-31.
117. Dong-Si T, Weber J, Liu JB, et al. Increased prevalence of the genetranscription by Chlamydia pneumoniae in cerebrospinal fluid ofpatients with relapsing-remitting multiple sclerosis. J Neurol 2004; 251: 542-7.
118. Gutierrez J, García M, Fernández F, et al. A meta-analysis ofhuman herpes virus 6 and Chlamydophila pneumoniae in multiplesclerosis. In: Columbus F, Ed. Focus on Multiple Sclerosis Research. New York: Nova Biomedical Books. 2004; pp. 165-97.
119. Hao Q, Miyashita N, Matsui M, Wang HY, Matsushima T, Saida T. Chlamydia pneumoniae infection associated with enhanced MRIspinal lesions in multiple sclerosis. Mult Scler 2002; 8: 436-40.
120. Saiz A, Marcos MA, Graus F, Vidal J, Jimenez de Anta MT. Noevidence of CNS infection with Chlamydia pneumoniae in patientswith multiple sclerosis. J Neurol 2001; 248: 617-8.
121. Sriram S, Yao SY, Stratton C, et al. Comparative study of thepresence of Chlamydia pneumoniae in cerebrospinal fluid ofpatients with clinically definite and monosymptomatic multiplesclerosis. Clin Diagn Lab Immunol 2002; 9: 1332-7.
122. Munger KL, Peeling RW, Hernan MA, et al. Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology 2003; 14: 141-7.
123. Yucesan C, Sriram S. Chlamydia pneumoniae infection of thecentral nervous system. Curr Opin Neurol 2001; 14: 355-9.
124. Kaufman M, Gaydos CA, Sriram S, Boman J, Tondella ML, Norton HJ. Is Chlamydia pneumoniae found in spinal fluid samplesfrom multiple sclerosis patients? Conflicting results. Mult Scler 2002; 8: 289-94.
125. Munger KL, De Lorenze GN, Levin LI, et al. A prospective studyof Chlamydia pneumoniae infection and risk of MS in two UScohorts. Neurology 2004; 62: 1799-803.
126. Swanborg RH, Whittum-Hudson JA, Hudson AP. Infectious agentsand multiple sclerosis: are Chlamydia pneumoniae and humanherpes virus 6 involved? J Neuroimmunol 2003; 136: 1-8.
127. Merelli E, Bedin R, Sola P, et al. Human herpes virus 6 and humanherpes virus 8 DNA sequences in brains of multiple sclerosispatients, normal adults and children. J Neurol 1997; 244: 450-4.
128. Ablashi DV, Lapps W, Kaplan M, Whitman JE, Richert JR, Pearson GR. Human herpesvirus-6 (HHV-6) infection in multiplesclerosis: a preliminary report. Mult Scler 1998; 4: 490-6.
129. Knox KK, Brewer JH, Henry JM, Harrington DJ, Carrigan DR. Human herpesvirus 6 and multiple sclerosis: systemic activeinfections in patients with early disease. Clin Infect Dis 2000; 31: 894-903.
130. Chapenko SD, Milers A, Nora Z, Logina I, Kukaine R, Murovska M. Correlation between HHV-6 reactivation and multiple sclerosisdisease activity. J Med Virol 2003; 69: 111-7.
131. Rotola A, Merlotti I, Caniatti L, et al. Human herpesvirus 6 infectsthe central nervous system of multiple sclerosis patients in the earlystages of the disease. Mult Scler 2004; 10: 348-54.
132. Tuke PW, Hawke S, Griffiths PD, Clark DA. Distribution andquantification of human herpesvirus 6 in multiple sclerosis andcontrol brains. Mult Scler 2004; 10: 355-9.
133. Clark DA. Human herpesvirus 6. Rev Med Virol 2000; 10: 155-73.
134. Rotola A, Caselli E, Cassai E, Tola MR, Granieri E, Luca DD. Novel human herpesviruses and multiple sclerosis. J Neurovirol 2000; 6: 88-91.
135. Rotola A, Cassai E, Tola MR, Granieri E, Di Luca D. Humanherpesvirus 6 is latent in peripheral blood of patients withrelapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 67: 529-31.
136. Taus C, Pucci E, Cartechini E, et al. Absence of HHV-6 and HHV-7 in cerebrospinal fluid in relapsing- remitting multiple sclerosis. Acta Neurol Scand 2000; 101: 224-8.
137. Alvarez-Lafuente R, Martin-Estefania C, de Las Heras V, et al. Active human herpesvirus 6 infection in patients with multiplesclerosis. Arch Neurol 2002; 59: 929-33.
138. Alvarez-Lafuente R, De las Heras V, Bartolome M, Picazo JJ, Arroyo R, Polman CH. Relapsing-remitting multiple sclerosis andhuman herpesvirus 6 active infection. Arch Neurol 2004; 61: 1523-7.
139. Marrie RA, Wolfson C, Sturkenboom MC, et al. Multiple sclerosisand antecedent infections: a case-control study. Neurology 2000; 54: 2307-10.
140. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virusantibodies and risk of multiple sclerosis: a prospective study. JAMA 2001; 286: 3083-8.
141. Haahr S, Plesner AM, Vestergaard BF, Hollsberg P. A role of lateEpstein-Barr virus infection in multiple sclerosis. Acta Neurol Scand 2005; 109: 270-5.
142. Levin LI, Munger KL, Rubertone MV, et al. Temporal relationshipbetween elevation of Epstein-Barr virus antibody titers and initialonset of neurological symptoms in multiple sclerosis. JAMA 2005; 293: 2496-500.
143. Nielsen TR, Rostgaard K, Nielsen NM, et al. Multiple sclerosisafter infectious mononucleosis. Arch Neurol 2007; 64: 72-5.
144. Munch M, Hvas J, Christensen T, Moller-Larsen A, Haahr S. Asingle subtype of Epstein-Barr virus in members of multiplesclerosis clusters. Acta Neurol Scand 1998; 98: 395-9.
145. Bray PF, Bloomer LC, Salmon VC, Bagley MH, Larsen PD. Epstein-Barr virus infection and antibody synthesis in patients withmultiple sclerosis. Arch Neurol 1983; 37: 94-6.
146. Sumaya CV, Myers LW, Willison GW, Ench Y. Increasedprevalence and titer of Epstein-Barr virus antibodies in patientswith multiple sclerosis. Ann Neurol 1985; 17: 371-7.
147. Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear antigenand viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985; 35: 435-8.
148. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis andrisk for multiple sclerosis: a meta-analysis. Ann Neurol 2006; 59: 499-503.
149. Hjalgrim H, Rasmussen S, Rostgaard K, et al. Familial clusteringof Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst 2004; 96: 780-4.
150. Vaughan JH, Riise T, Rhodes GH, Nguyen MD, Barrett-Connor E, Nyland H. An Epstein Barr virus-related cross reactiveautoimmune response in multiple sclerosis in Norway. J Neuroimmunol 1996; 69: 95-102.
151. Wagner HJ, Henning H, Jabs WT, Siekhaus A, Wessel K, Wandinger KP. Altered prevalence and reactivity of Epstein-Barrvirus antibodies in patients with multiple sclerosis. Viral Immunol 2000; 13: 497-502.
152. Lang HL, Jacobsen H, Ikemizu S, et al. A functional and structuralbasis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3: 940-3.
153. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003; 24: 584-8.
154. Munch M, Moller-Larsen A, Christensen T, Morling N, Hansen HJ, Haahr S. B-lymphoblastoid cell lines from multiple sclerosispatients and a healthy control producing a putative new humanretrovirus and Epstein-Barr virus. Mult Scler 1995; 1: 78-81.
155. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells andmultiple sclerosis. Lancet Neurol 2008; 7: 852-8.
156. Fleming JO, Cook TD. Multiple sclerosis and the hygienehypothesis. Neurology 2006; 67: 2085-6.
157. Leibowitz U, Atonovsky A, Medalie JM, Smith HA, Halpern L, Alter M. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry 1966; 29: 60-8.
158. Bach JF, Polman CH. The effect of infections on susceptibility toautoimmune and allergic diseases. N Engl J Med 2002; 347: 911-20.
159. Sotgiu S, Pugliatti M, Sotgiu A, Sanna A, Rosati G. Does the"hygiene hypothesis" provide an explanation for the highprevalence of multiple sclerosis in Sardinia? Autoimmunity 2003; 36: 257-60.
160. Ponsonby AL, van der Mei I, Dwyer T, et al. Exposure to infantsiblings during early life and risk of multiple sclerosis. JAMA 2005; 293: 463-9.
161. Fleming J, Fabry Z. The hygiene hypothesis and multiple sclerosis. Ann Neurol 2007; 61: 85-9.
162. Correale J, Farez M, Razzitte G. Helminth infections associatedwith multiple sclerosis induce regulatory B cells. Ann Neurol 2008; 64: 187-99.
163. Ascherio A, Munger KL. Environmental risk factors for multiplesclerosis. Part I: The role of Infection. Ann Neurol 2007; 61: 288-99.
164. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2000; 296: 2832-8.
165. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D asan immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008; 194: 7-17.